https://www.accesswire.com/708333/Lexarias-Human-Nicotine-Study-Nearing-Start-Date
Rigel Pharmaceuticals Q3 EPS $(0.11) Beats $(0.13) Estimate, Sales $22.41M Miss $22.61M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.12) per share